Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;57(2):118-22.
doi: 10.4103/0019-5154.94279.

Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis

Masoud Maleki  1 , Gholamreza Karimi, Mohsen Tafaghodi, Somayyeh Raftari, Yalda Nahidi
Affiliations

Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis

Masoud Maleki et al. Indian J Dermatol. 2012 Mar.

Abstract

Introduction: Cutaneous leishmaniasis is an endemic disease in developing countries caused by different species of leishmania parasite, and if left untreated, it will result in a deformed scar after a relatively long period. Although various systemic and topical treatments have been proposed for leishmaniasis, pentavalent Antimony compounds remain the first-line treatment for it. Considering the cases with treatment failure, potential side effects and reluctance of patients to receive the drug, there are continuing efforts to find better treatment alternatives.

Aim: Comparison of the effect of intralesional 2% zinc sulfate injection with Glucantime in treatment of acute cutaneous leishmaniasis.

Materials and methods: In this clinical trial, 45 patients with clinical diagnosis of cutaneous leishmaniasis and positive direct smear for leishman body were treated by intralesional injection of either 2% zinc sulfate or Glucantime. After simple randomization, in one group the patients were treated with 2 bouts of intralesional 2% zinc sulfate with a 2-week interval, and in the other group they were treated with 6 weekly bouts of intralesional Glucantime. The patients were monitored in two week intervals for 8 weeks. Healing of the lesions was evaluated clinically and by direct smear, and the data were analyzed using SPSS (11.5) software, t-Student, Mann-Whitney and Analysis of covariance (ANCOVA) statistical tests.

Findings: In the end of study, 34 patients completed the study, 10 of whom received intralesional Glucantime and 24 of whom received intralesional 2% zinc sulfate. The healing rate after 8 weeks was 80% in the group receiving intralesional Glucantime and 33.3% in the one receiving 2% zinc sulfate (P=0.009).

Conclusion: Based on the results of this study, intralesional injection of 2% zinc sulfate was less effective in treatment of cutaneous leishmaniasis than intralesional Glucantime.

Keywords: Cutaneous leishmaniasis; glucantime; intralesional injection; treatment; zinc sulfate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

Figures

Figure 1
Figure 1
Before treatment with zinc sulfate in a patient who responded to treatment
Figure 2
Figure 2
Necrosis and scar after treatment with zinc sulfate
Figure 3
Figure 3
Improvement of Figure 1 with zinc sulfate
Figure 4
Figure 4
Before treatment with zinc sulfate
Figure 5
Figure 5
After treatment of Figure 4 with zinc sulfate, without any response
See this image and copyright information in PMC

References

    1. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27:305–18. - PubMed
    1. Dowlati Y. Treatment of cutaneous leishmaniasis (Old World) Clin Dermatol. 1996;14:513–7. - PubMed
    1. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007;57:335.e1–29. - PubMed
    1. Lawn SD, Yardley V, Vega-Lopez F, Watson J, Lockwood DN. New World cutaneous leishmaniasis in returned travellers: Treatment failures using intravenous sodium stibogluconate. Trans R Soc Trop Med Hyg. 2003;97:443–5. - PubMed
    1. Najim RA, Sharquie KE, Farjou IB. Zinc sulphate in the treatment of cutaneous leishmaniasis: An in vitro and animal study. Mem Inst Oswaldo Cruz. 1998;93:831–7. - PubMed